The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, bringing forward several landmark advances in prostate cancer. Among them, the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial represent a major milestone in the management of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

From March 13–16, 2026, the 41st Annual Congress of the European Association of Urology (EAU26) was held at the ExCeL International Convention Centre in London, UK. As the largest and one of the most authoritative academic events in urology worldwide, the congress brought together leading experts from over 100 countries and regions to discuss cutting-edge advances and drive innovation in the field. At a featured scientific session, Prof. Ke Sun, representing the team led by Prof. Haixing Mai from the Chinese PLA General Hospital (301 Hospital), presented a study entitled:

With the publication of landmark studies such as EV302 and RC48-C016, the combination of antibody–drug conjugates (ADCs) and immunotherapy has firmly established its role as a new standard in the treatment of advanced urothelial carcinoma. Despite these advances, variability in clinical benefit remains evident, highlighting the need to identify more refined predictive biomarkers. 

The 41st Annual Congress of the European Association of Urology (EAU26) was recently held at the ExCeL International Convention Centre in London, UK. As one of the largest and most influential academic gatherings in global urology, the meeting brought together leading experts and scholars from over 100 countries and regions to discuss the latest advances and innovations in clinical practice.

During the 2026 European Association of Urology (EAU) Congress, Prof. Saad M.A. from the Department of Medical Oncology at the Mohammed V Military Teaching Hospital, Rabat, Morocco, presented a systematic review and reconstructed Individual Patient Data (IPD) meta-analysis. The study evaluated the clinical value of Bacillus Calmette-Guérin (BCG) combined with Immune Checkpoint Inhibitors (ICIs) in BCG-naive patients with high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC).

During the recent academic session, Professor Antoine Van Der Heijden from Radboud University Medical Center (Nijmegen, NL) shared comprehensive insights into the management of Muscle-Invasive Bladder Cancer (MIBC). The presentation focused on the clinical significance of histological subtypes, the inherent limitations of traditional Transurethral Resection of Bladder Tumor (TURBT), and the emerging value of MRI and Vi-RADS scoring in precision staging.

During a recent academic session, Professor Dingwei Ye (Prof. Dingwei Ye) from Fudan University Shanghai Cancer Center provided an in-depth interpretation of the Phase 1/2 clinical study data for SIM0237—an anti-PD-L1/IL-15 variant fusion protein—specifically in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

During the recent ASCO GU 2025 (Genitourinary Cancers Symposium), Professor Jiwei Huang from Renji Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine (on behalf of the research team led by Ding Yingjie), presented the updated efficacy and safety data from a multicenter, single-arm, Phase II trial. The study evaluates the combination of Fruquintinib and Serplulimab as a first-line (1st-line) treatment for patients with metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC).

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC) who are at risk of BCG-unresponsiveness or disease progression following treatment.

Dr. Biagio Antonio Maiorano from the Department of Medical Oncology, IRCCS San Raffaele Hospital (Milan, Italy), presented a sub-analysis of the ARON-1 study. This analysis evaluated the real-world incidence of grade 3–4 adverse events (AEs) and their clinical impact on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving first-line immune checkpoint inhibitor (IO)-based combination therapies.